Overview

A Study In Healthy Volunteers To Assess The Safety, Tolerability, And Relative Oral Bioavailability Of Three Formulations Of PH-797804

Status:
Completed
Trial end date:
2011-03-01
Target enrollment:
Participant gender:
Summary
There is no difference in the rate and extent of absorption of the material sparing tablet (MST), the Phase2b/3 formulation (P2b/3) with sodium lauryl sulphate (SLS) and the p2b/3 formulation without SLS.
Phase:
Phase 1
Details
Lead Sponsor:
Pfizer